country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-161506

Copy Link Print Information

PDE1-IN-7

PDE1-IN-7 (Compound 13h) is a selective inhibitor of bPDE1 (IC₅₀= 10 nM). PDE1-IN-7 exhibits significant anti-fibrotic effects in a BDL-induced liver fibrosis rat model. PDE1-IN-7 can be used for research in liver fibrosis.

For research use only. We do not sell to patients.

CAS No.: 3027833-49-1
Formula: C₃₂H₃₆F₂N₂O₆S
Molecular Weight:614.70

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (279 KB)

PDE1-IN-7 Chemical Structure

CAS No.: 3027833-49-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

PDEI

10 nM (IC₅₀)

All Phosphodiesterase (PDE) Isoforms :

In Vitro

PDE1-IN-7 (2.5-20 μM; 48 h) effectively inhibits TGF-β-induced myofibroblast differentiation and proliferation in LX-2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

human stellate cell LX-2
Concentration:

2.5, 5, 10, 20 μM
Incubation Time:

48 h
Result:

Dose-dependently reduced the elevated expression levels of fibronectin, collagen I, and α-SMA induced by TGF-β in LX-2 cells.

In Vivo

PDE1-IN-7 (i.p.; 2.5 mg/kg; once daily for 21 days) shows significant antifibrotic effects in a rat model of bile duct ligation-induced hepatic fibrosis^[1].

Pharmacokinetic Analysis in SD rats^[1]

Route	Dose (mg/kg)	t_1/2 (h)	C_max (ng/mL)	AUC_∞ (h)(ng·/mL)	Cl_obs (mL/min/kg)	MRT (h)	V_{ss_obs} (mL/kg)
i.v.	2.5	7.51 ± 0.64	25,006 ± 3082	6317 ± 839	6.56 ± 0.81	1.77 ± 0.07	698 ± 104

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BDL-induced hepatic fibrosis rats^[1]

Dosage:

2.5 mg/kg

Administration:

i.p.; once daily for 21 days

Result:

Significantly reduced alanine transaminase (ALT), aspartate transaminase (AST) and total bile acids (TBA) levels.
Reduced structural damage to liver tissue, decreased fibrotic foci, and lowered collagen deposition levels.
Significantly reduced protein expression levels at α-SMA and collagen I levels.
Significantly increased cAMP levels.

Chemical Information

CAS No. 3027833-49-1
Molecular Weight 614.70
Formula C₃₂H₃₆F₂N₂O₆S
SMILES

O=C1N(C(C(C(OCC2CCCCC2)=O)=C(N1)C)C3=CC=C(C(OCC4CC4)=C3)OC(F)F)C(SCC5=CC=CC=C5)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhao ZJ, et al. Design, Synthesis, and Evaluation of Dihydropyrimidine Derivatives as Selective PDE1 Inhibitors for the Treatment of Liver Fibrosis. J Med Chem. 2024 Apr 26. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PDE1-IN-7

All Phosphodiesterase (PDE) Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

PDE1-IN-7 Related Classifications

HY-161506 Related Classifications